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Soft connective tissue calciﬁcation is not a passive process, but the consequence of
metabolic changes of local mesenchymal cells that, depending on both genetic and
environmental factors, alter the balance between pro- and anti-calcifying pathways.
While the role of smooth muscle cells and pericytes in ectopic calciﬁcations has been
widely investigated, the involvement of ﬁbroblasts is still elusive. Fibroblasts isolated
from the dermis of pseudoxanthoma elasticum (PXE) patients and of patients exhibiting
PXE-like clinical and histopathological ﬁndings offer an attractive model to investigate the
mechanisms leading to the precipitation of mineral deposits within elastic ﬁbers and to
explore the inﬂuence of the genetic background and of the extracellular environment
on ﬁbroblast-associated calciﬁcations, thus improving the knowledge on the role of
mesenchymal cells on pathologic mineralization.
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CALCIFICATIONS IN SOFT CONNECTIVE TISSUES
For long time, unwanted calciﬁcation, as that occurring in arte-
rial calciﬁcation and in nephrolithiasis, has been considered as a
passive, physical–chemical phenomenon representing a degener-
ative, irreversible process often associated with aging (Shroff and
Shanahan, 2007). Many recent investigations, however, pointed
out that calcium and phosphate precipitation are the result of
complex and highly regulated series of events in which the balance
between calciﬁcation inducers and inhibitory mechanisms may
become severely deranged locally and/or systemically.
The deposition of calcium and phosphate in soft connective tis-
sues can be classiﬁed into three major categories: metastatic calci-
ﬁcation, dystrophic calciﬁcation, and calcinosis (Black and Kanat,
1985). Metastatic calciﬁcation occurs when calcium–phosphorous
levels are elevated mainly due to metabolic/hormonal alterations
and/or to tumor-associated complications. Dystrophic calciﬁca-
tion takes place in the presence of damaged or necrotic tissue as
in atherosclerosis. Calcinosis is generally associated to hypovas-
cularity or hypoxia, it may involve a localized area or it may be
widespread, causing secondary muscle atrophy, joint contractures
and skin ulceration, with recurrent episodes of inﬂammation or
infection (Boulman et al., 2005).
In most cases, mineral deposition develops in the extracel-
lular environment without being localized on speciﬁc matrix
components/structures. A typical example is represented by “cal-
ciphylaxis,” a rare disease in which a generalized calciﬁcation is
associated with thrombotic cutaneous ischemia and necrosis, thus
causing a mortality rate ranging from 60 to 80% due to wound
infection, sepsis, and subsequent organ failure (Arseculeratne
et al., 2006; Hoff and Homey, 2011).
As clearly shown by several experimental ﬁndings and clin-
ical observations, calciﬁcation may also occur in a number
of genetic diseases, in metabolic disorders, such as uremia,
hyper-parathyroidism, and diabetes, or in areas without adja-
cent inﬂammation or atherosclerosis. Due to the heterogeneity
of factors contributing to the development of calciﬁcations, many
studies have been carried out in order to ﬁnd common patho-
genetic mechanisms and to identify possible druggable targets
(i.e., single molecules and/or signaling pathways). Within this
framework, numerous proteins have been identiﬁed to be involved
in bone calciﬁcation as well as in ectopic mineralization. It
has been suggested that an active and dynamic balance of pro-
and anti-calcifying mechanisms occurs in both physiological and
pathological calciﬁcation (Abedin et al., 2004) and that mesenchy-
mal cells are key players, not only because they synthesize most
of the mineral regulatory proteins, but also because they are
responsible for the qualitative and quantitative characteristics of
the extracellular environment, where apatite ectopic deposition
arises.
ROLE OF PRO- AND ANTI-CALCIFYING FACTORS IN ECTOPIC
CALCIFICATION
The role of calcitropic hormones, namely catecholamines,
parathyroid hormone (PTH), and vitamin D or 1,25(OH)2D3 on
calcium metabolism is well-known (Rizzoli and Bonjour, 1998).
However, in the last decade, a growing number of evidence is
highlighting the importance of many other molecules as part
of a composite network that, on the basis of common struc-
tural components, exhibits peculiar interactions and/or undergoes
different regulatory mechanisms depending on the tissue [e.g.,
osteoprotegerin (OPG) or matrix Gla protein (MGP) in bone and
vascular tissue; Kornak, 2011] and on the environmental con-
text. In addition, these molecules can be produced and locally
secreted by mesenchymal cells, or can diffuse from circulation to
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peripheral tissues, where they may exert different effects on local
calcium/phosphate homeostasis (Figure 1).
The mechanisms of calciﬁcation in skeletal and dental tissues
have been under investigation since long time. One common fea-
ture to almost all physiological mineralization mechanisms seems
the involvement of small (20–200 nm) membrane particles, called
matrix vesicles (MVs). They bud off from the plasma membrane
of mineralizing cells and are released into the pre-mineralized
organic matrix serving as a vehicle for the concentration of ion
or ion-enriched substrates, which are required for the activity
of membrane-bound enzymes triggering mineral deposition at
speciﬁc sites.
The observation thatMV-likemembranes are present in a num-
ber of ectopic calciﬁcation processes supports the concept that the
mechanisms of vascular calciﬁcation are similar to those seen in
normal skeletal development (Golub, 2011).
However, soft connective tissue calciﬁcations activate a num-
ber of common pathways, but, at the same time they may exhibit
local speciﬁc variations (e.g., in different tissue/body regions),
possibly depending on the genotypic/phenotypic peculiarities of
each mesenchymal cell type/subtype. Mineralization of dermal
constituents, for instance, has been never associated with MVs,
indicating that ﬁbroblasts, differently from smooth muscle cells,
can be responsible for mineral deposition, even in the absence of
MVs. It could be, therefore, hypothesized that the role of mes-
enchymal cells in ectopic calciﬁcation may differ depending on
the ability of the cell type to acquire a bone-oriented phenotype.
To further increase the complexity and the heterogeneity of
mechanisms regulating pathologic calciﬁcation there are stud-
ies demonstrating that factors promoting or inhibiting ectopic
calciﬁcations are under the control of different genes, as in
the case of extracellular pyrophosphate (PPi), a small molecule
made of two phosphate ions, linked by an ester bond, that reg-
ulates cell differentiation and serves as an essential physiologic
inhibitor of calciﬁcation by negatively interfering with crystal
growth (Terkeltaub, 2001). The amount of extracellular PPi is reg-
ulated by two different gene products, as it originates either from
the breakdown of nucleotide triphosphates by the ectonucleotide
pyrophosphatase/phosphodiesterase (PC-1/ENPP1) or from the
PPi transport by the transmembrane ankylosis protein homolog
(ANKH). Consistently, either mutations or knockdown of these
genes can induce hyper-mineralization of aorta (i.e., generalized
FIGURE 1 | Major factors involved in mineral deposition. AMP,
adesosine monophosphate; ANKH, ankylosis protein homolog; ATP,
adenosine triphosphate; BMP2, bone morphogenetic protein-2; BMP2R,
bone morphogenetic protein-2 receptor; BSP, bone sialoprotein; Ca,
calcium; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase;
Glu- and Gla-MGP, uncarboxylated- and carboxylated-matrix Gla protein;
OPG, osteoprotegerin; OPN, osteopontin; Pi, inorganic phosphate; Pit-1,
phosphate transporter-1; PPi, pyrophosphate; RANKL, receptor activator of
nuclear factor kappa-B ligand; TNAP, tissue non-speciﬁc alkaline
phosphatase.
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arterial calciﬁcation in infants or GACI) and of ligaments and
articular cartilage (i.e., chondrocalcinosis) in humans and mice,
respectively (Okawa et al., 1998; Ho et al., 2000; Pendleton et al.,
2002; Rutsch et al., 2003).
In the extracellular space, phosphate levels are directly con-
trolled by tissue non-speciﬁc alkaline phosphatase (TNAP), a cell
membrane-bound ecto-enzyme that increases inorganic phos-
phate availability by releasing it from a variety of phosphate-
enriched substrates and, at the same time, reduces the levels of
calciﬁcation inhibitors, promoting the hydrolysis of PPi and the
dephosphorylation of osteopontin (OPN; El-Abbadi et al., 2009;
Orimo, 2010). As a consequence, expression and activity of TNAP
are associated either with physiological and pathological calciﬁ-
cations, although changes in enzyme activity may not be directly
proportional to the level of mineralization, which is actually the
result of the activity of many genes/proteins (Mendes et al., 2004).
Consistently, increased TNAP expression and activity have been
observed in CD73 deﬁciency, a disorder that, due to mutations
in NT5E (a gene encoding for the membrane-bound ecto-enzyme
that cleaves adesosine monophosphate (AMP) to adenosine and
inorganic phosphate), is characterized by tortuosity and calciﬁca-
tion of lower limb arteries and by mineralization of hand and foot
joint capsules (StHilaire et al., 2011).
Alkaline phosphatase, similarly to other osteogenic genes, as
type I collagen, osteocalcin (OC), and bone sialoprotein (BSP),
can be transcriptionally regulated by bone morphogenetic protein
2 (BMP2; Kim et al., 2004), a powerful cytokine that, by activating
Smad signaling pathways, promotes differentiation of mesenchy-
mal cells into osteoblasts in vitro and induces bone formation in
vivo (Rosen, 2009). Consistently, in ﬁbrodysplasia ossiﬁcans pro-
gressiva endochondral ossiﬁcation is triggered by BMP signaling
in muscle cells (Shen et al., 2009). It has been demonstrated that
treatment of smooth muscle and bone cell cultures with BMP2 (i)
promotes osteogenic phenotype transition of smooth muscle cell
(SMC; i.e., up-regulation of Runx2/Cbfa1 and down-regulation
of SM22 expression), (ii) enhances elevated phosphate-induced
calciﬁcation, but does not induce calciﬁcation under normal phos-
phate conditions. These results clearly indicate that phosphate
transport via Pit-1 is crucial in BMP2-mediated calciﬁcation and
in cell phenotype modulation (Suzuki et al., 2006; Li et al., 2008).
Pit-1 is a type III sodium-dependent phosphate co-transporter
that, through the activation of the Erk 1/2 signaling pathways, pro-
motes calciﬁcation and favors changes of vascular smooth muscle
cell (VSMC) toward an osteochondrogenic phenotype. Moreover,
it has been shown that Pit-1 may exert effects also at the endo-
plasmic reticulum level. Studies on VSMC revealed that, when
these cells are treated with platelet-derived growth factor (PDGF),
they exhibit increased Pit-1 expression and it has been hypothe-
sized that Pit-1 may regulate anti-calciﬁcation proteins (such as
MGP), as well as kinases able to phosphorylate secreted matrix
proteins (such as OPN; Villa-Bellosta et al., 2007). In addition,
recent evidence has been provided that Pit-1 have other unex-
pected functions in cell proliferation and embryonic development
(Lau et al., 2010), thus emphasizing the regulatory importance of
phosphate in cell behavior.
Another protein favoring calciﬁcation is BSP, originally identi-
ﬁed in bone and at sites of ectopic calciﬁcation in blood vessels,
heart valves, and skeletal muscle. It is involved in the early stages
of mineralization and bone desorption, since it is immobilized
on collagen ﬁbrils where the poly-glutamic acid sequences of BSP
act as possible nucleation sites for hydroxyapatite crystals. BSP,
together with another bone phosphoprotein named OPN, can
modulate crystal shape by adsorption on a speciﬁc face of the
crystals (Ganss et al., 1999).
Osteopontin is in fact a highly phosphorylated and glycosy-
lated secreted protein originally discovered in bone, but identiﬁed
also in calciﬁed vascular lesions (Giachelli et al., 1993), where it
may counteract apatite deposition by physically inhibiting crys-
tal growth (Boskey et al., 1993) and/or by up-regulating the
expression of genes, as carbonic anhydrase II, favoring mineral
absorption, mainly through the activation of macrophage activi-
ties (Rajachar et al., 2009). These properties depend on the level
of OPN phosphorylation as well as on the targeted tissue (i.e.,
bone or soft connective tissues; Jono et al., 2000). Recent evidence
puts forward that OPN is actually a multi-functional protein able
to interact with several integrin receptors, thus playing a role in
activation, adhesion and migration of many cell types, not only in
tissue mineralization and tumor growth, but also in inﬂammation
(Jahnen-Dechent et al., 2008). These broad biological activities
underlie the presumed role of OPN in the pathogenesis of cardio-
vascular diseases, including atherosclerosis and abdominal aortic
aneurysm (Giachelli and Steitz, 2000), thus paving the way toward
the clinical use of OPN plasma levels as biomarker of inﬂamma-
tion and as predictor of the risk for cardiovascular complications
(Cho et al., 2009).
Another interesting protein is OPG that serves as a decoy
receptor for the receptor activator of nuclear factor κB-ligand
(RANKL) and acts as an inhibitor of osteoclastogenesis and osteo-
clast activation by blocking RANK activation (Boyle et al., 2003;
Van Campenhout and Golledge, 2009). As demonstrated in the
KO animals, the absence of OPG is associated with osteoporosis
as well as with calciﬁcations of aorta and renal arteries (Bucay
et al., 1998). Therefore, within the vasculature, OPG may exert a
protective role toward ectopic calciﬁcation down-regulating alka-
line phosphatase activity (Van Campenhout and Golledge, 2009).
Consequently, serumOPG levels have been signiﬁcantly associated
with thepresenceof coronary arterydisease (Jono et al.,2002), sug-
gesting that OPG may represent a strong risk factor for mortality
in dialysis patients (Morena et al., 2006).
Matrix Gla protein belongs to a large family of proteins whose
maturation requires vitamin K-dependent carboxylation of glu-
tamyl residues (Schurgers et al., 2007; O’Young et al., 2011). It is
considered the most active anti-calcifying agent in vessels (Shana-
han et al., 1998; Price et al., 2006), but it is actually produced by
several cell types, among which VSMCs, osteoblasts, and ﬁbrob-
lasts (Davies et al., 2006; Park et al., 2006). The phenotype of
MGP−/− mice is characterized by arterial calciﬁcation and by
arterial-venous malformations (Yao et al., 2011), suggesting that
MGP has roles in connective tissue development and homeostasis,
as well as in preventing ectopic calciﬁcation. The corresponding
human disorder is Keutel syndrome (Munroe et al., 1999), charac-
terized by enhanced mineralization of the growth plate cartilage
leading to reduced longitudinal growth and osteopenia, as well
as calciﬁcation of the elastic lamellae in the arterial wall due to
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chondrocyte transformation of VSMCs. This aberrant cellular dif-
ferentiation could be related to the ability of MGP to act as a
regulator of BMP2 in a dose-dependent manner. Low levels of
MGP relative to BMP2 may result in mild enhancement of BMP2
activity, whereas intermediate levels would inhibit and high lev-
els strongly increase BMP2 activity (Zebboudj et al., 2002). These
ﬁndings clearly demonstrate the complexity of the mechanisms
regulating ectopic calciﬁcations, which are dependent not only
on the presence/absence of speciﬁc proteins and on their activity
(due, for instance, to post-translationalmodiﬁcations as phospho-
rylation and carboxylation), but also on the ratio among different
molecules.
A similar vitaminK-dependent carboxylated protein isOC that,
synthesized by osteoblasts, is deposited into bones, where it con-
trols the size and the speed of crystal formation and acts as a
chemo-attractant for osteoclasts (Roach, 1994). Moreover, it is
released into circulation, where it is also used as a biomarker of
bone metabolism and vitamin K status. The increase of under-
carboxylated OC (ucOC) levels in the aging population led to
the hypothesis that vitamin K insufﬁciency might be related to
the calciﬁcation paradox (namely age-dependent bone loss asso-
ciated to vascular calciﬁcation), however, clinical trials did not
provide support to the hypothesis that vitamin K supplementa-
tion will reduce bone loss or fracture risk. Very recent results
from in vitro and in vivo experimental models indicate that
ucOC is an active hormone with a positive role on glycemia.
If this hypothesis will be proved also in humans, vitamin K
supplementation, by decreasing ucOC,might exert unknown, pos-
sibly detrimental, effects on glucose metabolism (Gundberg et al.,
2012). This hypothesis sustains the importance to perform broad
and extended investigations when diet regimens, supplemented
with evenphysiological/endogenous components, are used as ther-
apeutic tools. Interference with a speciﬁc molecule may in fact
have“domino”consequences onmany other, apparently unrelated,
pathways.
Finally, a novel γ-carboxyglutamate (Gla)-containing protein,
named Gla-rich protein (GRP) due to its high content in Gla
residues, has been identiﬁed in association with chondrocytes
and bone cells. Although its molecular function is yet unknown,
the high content of Gla residues and its accumulation at sites of
pathological calciﬁcation in skin, vascular systemandbreast cancer
tumors suggest that GRP modulates calcium availability, regulates
cartilage matrix organization and inﬂuences matrix stability being
associated with ﬁbrillar collagens (Cancela et al., 2012).
Although not synthesized by mesenchymal cells, being secreted
from hepatocytes into the circulation, never the less, fetuin A
exerts its biological role in the periphery, where it inhibits calciﬁca-
tion by the transient formation of soluble colloidal spheres (Heiss
et al., 2003). It binds calcium phosphate and calcium carbonate
with high afﬁnity and, although with lower efﬁciency, magnesium
phosphate (Schinke et al., 1996). In rat sera fetuin A is present
in high molecular weight complexes, termed “calciprotein” parti-
cles, which contain calcium, phosphate and matrix Gla protein.
They act as inhibitors of mineralization in solution and of cell-
mediated mineralization by inhibiting the de novo formation
of calcium phosphate without dissolving preformed minerals
(Schlieper et al., 2007).
The complexity of the mechanisms regulating pathologic cal-
ciﬁcation is further highlighted by the involvement of apparently
unrelated gene products, as it was noticed for Klotho and multi-
drug resistance protein 6 (MRP6), just to mention few of them.
Klotho is a transmembrane protein with an extracellular (β-
glucosidase domain that can be shed from the plasma membrane
by Adamts proteases and, in addition to its enzymatic function,
binds directly to ﬁbroblast growth factor (FGF)23 acting as an
essential FGF-coreceptor. In the kidney, FGF23 signalling leads to a
down-regulation of the sodium/phosphate co-transporter (NaPi)
and of the vitamin D 1α-hydroxylase. Therefore, Klotho deﬁ-
ciency, in spite of high FGF23 levels and of high 1,25-dihydroxy
vitamin D3 and calcium concentrations, leads to osteopenia,
hyper-phosphatemia, and consequently widespread vascular and
soft tissue calciﬁcations (Moe, 2012). By contrast, dysfunction
of the ATP-binding cassette (ABC)-transporter ABCC6 (cod-
ing for the transmembrane protein MRP6 highly expressed in
liver and kidney) causes pseudoxanthoma elasticum (PXE), a
rare disease characterized by mineralization and degeneration
of elastic ﬁbers within soft connective tissues, thus causing skin
laxity, cardiovascular complications, and visual impairment in
a setting of normal levels of circulating calcium and phosphate
and without bone abnormalities (see ahead for further details;
Quaglino et al., 2011).
ROLE OF THE EXTRACELLULAR MATRIX IN ECTOPIC CALCIFICATION
Changes in the characteristics of the extracellular matrix and
in the ratio between matrix constituents inﬂuence not only the
mechanical properties of connective tissues, but signiﬁcantly
contribute to modulate cell phenotype by altering integrin expres-
sion, focal adhesions, cytoskeletal organization and consequently
intracellular signaling pathways.
As a consequence, it has been shown that osteogenic differen-
tiation of calcifying VSMCs was promoted by type I collagen and
ﬁbronectin, but it was inhibited by type IV collagen. By contrast,
valvular interstitial cells (a heterogeneous population of ﬁbrob-
lasts, with a small percentage of myoﬁbroblasts and smoothmuscle
cells ranging from 5 to 30% in physiological or pathological con-
ditions, respectively) when grown on type I collagen or ﬁbronectin
remain in a quiescent ﬁbroblastic state, whereas those cultured on
ﬁbrin surfaces exhibit amyoﬁbroblast phenotype and rapidly form
calciﬁed aggregates (Chen and Simmons, 2011). These data fur-
ther highlight the complex interactions between cells and between
cells and matrix.
Therefore, beside alterations in the balance between pro- and
anti-calcifying factors, changes in the extracellular matrix may
signiﬁcantly contribute to mineral deposition. It is noteworthy to
mention that in soft connective tissues, if mineralization is not
triggered by necrotic cell debris, elastic ﬁbers seem to represent
the selected target of pathologic mineralization, possibly due to
their low turnover and/or susceptibility to calcium ion-binding
(Pugashetti et al., 2011).
Puriﬁed elastinhas beendemonstrated tohave calcium-binding
capabilities (Molinari-Tosatti et al., 1968; Cox et al., 1975; Long
and Urry, 1981). Moreover, addition of elastin peptides to cul-
tured SMC enhances Von Kossa positive calcium precipitates in
the phosphate model of in vitro calciﬁcation (Hosaka et al., 2009).
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In accordance with these data, elastin degradation due to the
up-regulation of matrix metalloproteinase (MMP)2, MMP9, and
cathepsin S has been shown to increase arterial calciﬁcation in the
uremic mice model of ectopic calciﬁcation (Pai et al., 2011) and
to favor calciﬁcation of native heart valves (Perrotta et al., 2011).
It has been therefore suggested that peptides or fragments derived
from elastin degradation, due to their high hydrophobicity and
coacervation properties, may enhance abnormal mineralization
(Abatangelo et al., 1975; Long et al., 1975) leading to the formation
of abnormal complexes with high calcium-binding capabili-
ties (Bell et al., 1974; Tamburro et al., 1977; Urry et al., 1982).
These ﬁndings sustain the association between inﬂammation and
ectopic calciﬁcation, especially in the vascular compartment (Shao
et al., 2010).
Beside elastin itself, elastic ﬁbers are made of several compo-
nents whose exposure, with age and in pathological conditions,
further contributes to the preferential localization of ectopic cal-
ciﬁcations on elastin and on elastic ﬁber-associated molecules.
For instance, calcium-binding sites have been found on speciﬁc
domains in ﬁbrillin I (Handford, 2000), one of the principal
elastin-associated proteins. Therefore, not only elastin per se, but
also elastic ﬁbers, as a whole, could function as nucleation center
for calcium precipitation (Starcher and Urry, 1973). Beside ﬁb-
rillin, proteoglycans (PG), glycosaminoglycans (GAGs), and other
glycoproteins present inside elastic ﬁbers could also represent
additional calcium-binding sites.
We have repeatedly demonstrated that GAGs are present inside
elastic ﬁbers, possibly regulating the mechanical properties and
stability of these ﬁbers (Pasquali-Ronchetti et al., 1984; Contri
et al., 1985). Changes in the type or ratio of GAGs, as those occur-
ring with age, in the course of pathologic conditions or depending
on tissue or on speciﬁc physiological requirements (Berenson et al.,
1985; Cherchi et al., 1990; Passi et al., 1997; Qu et al., 2011), may
inﬂuence the characteristics of elastic ﬁbers and of thewhole extra-
cellular matrix, as demonstrated for instance in the vasculature
where connective tissue molecules follow a gradient depending
on the distance from the heart (Madhavan, 1977). Moreover, we
have also demonstrated that calciﬁed elastic ﬁbers exhibit pecu-
liar type and localization of PG/GAGs such as heparan sulfate,
putting forward the hypothesis that GAGs have a role in elastic
ﬁber homeostasis as well as in the calciﬁcation process (Passi et al.,
1996; Gheduzzi et al., 2005).
Furthermore, it was shown that, in cartilage, PG/GAGs act as
calcium-concentrating agents promoting calciﬁcation, but they
also behave as inhibitors of hydroxyapatite formation functioning
as a cation-exchanging calcium reservoir (Hunter, 1991). Consis-
tently, decorin, a small leucine-rich PG containing one dermatan
sulfate or chondroitin sulfate chain, beside its regulatory role on
transforming growth factor (TGF)-β activity and collagen ﬁbril-
logenesis, binds to hydroxyapatite (Boskey et al., 1997; Rees et al.,
2001; Mochida et al., 2009) and colocalizes with areas of calciﬁca-
tion in skeletal tissues, in the adventitia of blood vessels, and in the
skin (Hocking et al., 1998).
A further link between GAGs and the calciﬁcation pro-
cess is the ability of BMPs to bind to heparin and to
induce osteoblast differentiation of mesenchymal cells. Moreover,
heparan sulfate and dextran sulfate enhanced BMP2 activity
serving as ligands to their signaling receptors on cell membranes
(Takada et al., 2003).
ROLE OF MESENCHYMAL CELLS IN SOFT CONNECTIVE
TISSUE CALCIFICATIONS
PERICYTES
The presence of perivascular cells closely associated with capillar-
ies was described more than 100 years ago, although their origin
remained elusive formany decades (Díaz-Flores et al., 1991). Some
studies proposed that they may derive from the neural crest,
whereas other studies suggested that pericytes derive from smooth
muscle cells, ﬁbroblasts, endothelial cells, and bone marrow and
that they exhibit a multi-lineage potential being capable of dif-
ferentiating into a variety of cell types including osteoblasts and
chondrocytes, as demonstrated, both in vitro and in vivo experi-
mentalmodels. On the basis of these observations, it was suggested
that pericytes play a role in mediating ectopic calciﬁcation (Collett
and Canﬁeld, 2005).
There is now good evidence that angiogenesis regulates ectopic
calciﬁcation in several ways: (i) angiogenic factors are mitogenic
for mesenchymal cells and osteoblasts and enhance bone for-
mation in vivo; (ii) cytokines as BMP2 and BMP4, released by
endothelial cells, induce both the differentiation of osteoprogeni-
tor cells and calciﬁcation in vitro and in vivo, although this effect
is context-dependent (Shin et al., 2004); (iii) new vessels serve as a
conduit for osteoprogenitor cells that may derive from the circu-
lation or from pericytes themselves. Consistently, the association
between angiogenesis and ectopic calciﬁcation has been noted in
several cases, as in ductal carcinoma in situ, in calcifying ﬁbrob-
lastic granuloma, in choroidal osteoma and in the calciﬁcations of
the retina.
When cultured in standard growth medium, pericytes undergo
a process of growth anddifferentiation characterized by the forma-
tion, within approximately 8 weeks, of largemulti-cellular nodules
that, similarly to the matrix found in calciﬁed vessels, contain type
I collagen, OPN, matrix Gla protein and OC and hydroxyapatite
crystals with a calcium to phosphate ratio analogous to that of
bone (Doherty and Canﬁeld, 1999; Abedin et al., 2004).
VASCULAR SMOOTH MUSCLE CELLS
Studies in human lesions and mouse models of arterial calciﬁca-
tion as well as in vitro calciﬁcation models of human and bovine
VSMC support the concept that mesenchymal-derived vascular
cells participate in mineral deposition by mimicking bone for-
mation, since they exhibit several hallmarks of endochondral
ossiﬁcation (Liu and Shanahan, 2011).
It has been clearly demonstrated that VSMC (1) undergo
osteoblastic differentiation with loss of smooth muscle-speciﬁc
gene expression and gain of osteoblast-like properties, includ-
ing expression of the osteoblast differentiation factor Cbfa-1;
(2) activate the mineralization process in the presence of high
concentrations of extracellular phosphate; (3) may require a
sodium-dependent phosphate co-transporter function to calcify
(Giachelli, 2001; Vattikuti and Towler, 2004). The complexity of
VSMC phenotypic changes associated to ectopic calciﬁcations has
been recently clearly outlined by a whole-genome expression array
approach in uremic rats fed on a high phosphate diet. It was in fact
www.frontiersin.org March 2013 | Volume 4 | Article 22 | 5
“fgene-04-00022” — 2013/3/12 — 13:07 — page 6 — #6
Ronchetti et al. Fibroblasts in ectopic calciﬁcations
demonstrated that the transition from “muscle-related” to “bone-
related” gene expression involved the deregulation of at least 53
genes (Román-García et al., 2010) and the activation of Erk1/2
and Wnt pathways (Lau et al., 2010).
Interestingly, it has been shown that, in appropriate culture
conditions, approximately 10–30% of VSMC have the capacity to
express osteoblast differentiationmarkers and to retain this pheno-
type through in vitro passages (Boström et al., 1993). In agreement
with these in vitro data, a variety of bone matrix proteins and
regulatory factors have now been demonstrated in human calci-
ﬁed plaque, including OC, BSP, osteonectin, collagen I, alkaline
phosphatase, Msx-2, and Cbfa-1.
FIBROBLASTS
Many studies performed on VSMC demonstrated that mesenchy-
mal cells, whether locally producing pro- and anti-calcifying
factors or being involved in extracellular matrix synthesis and
degradation, are involved in the mineralization of soft connective
tissues. Never the less, a key question is whether all mesenchy-
mal cells behave similarly, or if differences in their tissue-speciﬁc
differentiation may be associated to a different susceptibility of
connective tissues to mineralize.
For instance, skin seems to be only rarely affected by ectopic
calciﬁcation in contrast to the vascular system. Very few studies
have been done on ﬁbroblasts and especially on dermal ﬁbroblasts,
although in a number of disorders there is a clear evidence for their
close association to ectopic calciﬁcations (Figure 2).
Among the few reports on ﬁbroblast-associated calciﬁcations
are those showing that a human gingival ﬁbroblast cell line may
exhibit both intracellular and extracellular ectopic mineralization
starting within round and irregularly shaped vesicles contained
in large cytoplasmic vacuoles. This may suggest that mineral
FIGURE 2 |Transmission electron microscopy of a dermal biopsy from
a patient affected by pseudoxanthoma elasticum (PXE). Deformed
calciﬁed elastic ﬁbers (E) are present in close proximity to large ﬁbroblasts
with abundant and dilated cisternae of the endoplasmic reticulum. Collagen
ﬁbrils occasionally organized into collagen ﬂowers (arrows) are also visible.
Bar = 1 μm.
accumulation and transformation of amorphous mineral into
crystalline structures take place within cellular vesicular structures
like MV (Yajima et al., 1984).
By contrast, MV have been never observed within or around
dermal ﬁbroblasts in areas of matrix calciﬁcation in vivo nor
in the high phosphate-calciﬁcation model in vitro (personal
observations). This ﬁnding indicates the occurrence of different
phenotypic characteristics between dermal and gingival ﬁbrob-
lasts, but at the same time demonstrates that mineral deposition
can be observed also independently from MV.
In the attempt to understand the interactions between cells
from hard and soft connective tissues and to unveil the complexity
of the mechanisms involved in ﬁbroblast-associated calciﬁca-
tion, Yu and coworkers performed a cDNA microarray analysis
on ﬁbroblasts from spinal ligaments cultured in the presence
of conditioned media of osteoclast-like cells. In this environ-
ment ﬁbroblasts exhibited high levels of alkaline phosphatase and
mineral deposition, but more interestingly, microRNA expres-
sion proﬁles revealed a signiﬁcant down-regulation of a group
of microRNAs known to negatively interfere with genes associ-
ated with osteogenic differentiation (e.g., BMP2, OC, Runx2).
In the light of these data, it has been hypothesized that osteo-
clasts might induce the osteogenic differentiation of ﬁbroblasts in
vitro and that miRNA may play an important role in the regu-
lation of cell–cell interactions between osteoclasts and ﬁbroblasts
(Yu et al., 2011).
An additional demonstration of the ability of ﬁbroblasts to
modulate their phenotype in response to speciﬁc environmen-
tal characteristics has been provided by studies on rat dermal
ﬁbroblasts cultured in the presence of elastin degradation products
and of TGF-beta1. Mineralization was preceded by up-regulation
of alpha-smooth muscle actin, type I collagen and MMP2,
which are characteristic features of myoﬁbroblasts. Thereafter,
osteogenic markers as OC, alkaline phosphatase, and osteoprote-
gerin increased their expression and, after 21 days, multi-cellular
calciﬁed nodules were observed. It was proposed that elastin-
associated mineralization might result from defective/unbalanced
dynamic remodeling events similar to those occurring during the
repair process (Simionescu et al., 2007).
Therefore, it is important to note that, irrespective of the cell
type, a speciﬁc environment is required for calciﬁcation tooccur, in
vivo, but especially in vitro. All cultured mesenchymal cells, in fact,
are dependent for their growth on a variety of cytokines and adhe-
sive molecules as those easily provided by addition of fetal/calf
bovine serum. However, the amount of “serum factors” signiﬁ-
cantly higher compared to physiological “in vivo” concentrations,
provide cells of a number of other components that, depending on
the characteristics of the serum, directly inﬂuences the mineraliza-
tion process or may regulate cell behavior and, as a consequence,
the expression of speciﬁc gene/proteins. Among these factors,
serum fetuin A, that is usually present in cell culture media, repre-
sents a powerful inhibitor of the calciﬁcation process making cells
unable to mineralize in standard cell culture conditions. To over-
come this problem, it is possible to utilize serum-free media (i.e.,
media with chemically deﬁned components and supplements)
and/or to add to standard cell cultures [in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) plus serum] high concentrations of
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phosphate (that can easily precipitate as soon as it forms complexes
with calcium) or of phosphate donor substrates (that require an
active involvement of cells for the enzymatic release of inorganic
phosphate from substrates). Human skin-derived ﬁbroblast pre-
cursor cells, for instance, can acquire an osteoblast-like behavior
and start to mineralize the newly deposited extracellular matrix
only if cultured in a pro-osteogenic medium (supplemented with
ascorbic acid, beta-glycerophosphate, and dexamethasone); as a
result induced expression of alkaline phosphatase, BSP and OC
leads to mineral deposition (Buranasinsup et al., 2006).
A further difference, between mesenchymal cell types is the
time required in vitro to obtain a calciﬁed matrix, which may be
taken as predictive of the pro-osteoblastic potential of the cells.
In osteoblast and VSMC cultures, mineralization can be obtained
after 3–5 or 8–10 days in culture, respectively (Uchimura et al.,
2003; Li et al., 2004). By contrast, mineralized matrix becomes
clearly evident only after 2–3 weeks in dermal ﬁbroblast cultures
(Boraldi et al., in press; Figure 3).
On the basis of these results it could be hypothesized that der-
mal ﬁbroblasts are rather resistant to be converted into osteoblast-
like cells, in agreement with the uncommon occurrence of dermal
calciﬁcations.
Interestingly, ectopic soft tissue calciﬁcation is a well-known
symptom in Werner syndrome (WS), an autosomal recessive
progeroid disorder caused by mutations in RecQ DNA heli-
case. Cultured ﬁbroblasts from WS patients undergo spontaneous
mineralization in vitro at normal phosphate concentration, and
overexpress Pit-1 at mRNA and protein levels. Both calciﬁca-
tion and Pit-1 up-regulation have been also detected in situ in
the skin of patients (Honjo et al., 2008), supporting the concept
that dermal ﬁbroblasts mimic and retain in vitro at least some of
the pathologic characteristics they have in vivo, thus representing
a valuable model to investigate the pathogenetic mechanisms of
diseases.
PXE AND PXE-LIKE DISORDERS AS MODELS FOR
INVESTIGATING THE ROLE OF FIBROBLASTS IN SOFT
CONNECTIVE TISSUE CALCIFICATIONS
PSEUDOXANTHOMA ELASTICUM
Pseudoxanthoma elasticum is a rare genetic disorder characterized
by skin papules on the neck, axillae, and groin, often associated
with skin redundancy and laxity, by retinal alterations as angioid
streaks andneovascularization, andbymiddle sized artery narrow-
ing up to occlusion. All these alterations depend on the deposition
of calcium minerals inside or associated with elastic ﬁbers (Truter
et al., 1996; Gheduzzi et al., 2003; Figure 2). The phenomenon is
rather peculiar as calciﬁcations affect only elastic ﬁbers, whereas
collagen does not calcify; moreover, this abnormal mineral-
ization occurs in the absence of increased calcium and phos-
phate levels, in the total absence of inﬂammation, cell necrosis,
apoptosis.
Pseudoxanthoma elasticum has been associated to mutations
in the ABCC6 gene, a member of the ABC family of mem-
brane transporters (it encodes for the membrane transporter
MRP6), that is mainly expressed in liver and kidney (Bergen
et al., 2000; Le Saux et al., 2000; Ringpfeil et al., 2000), whereas
its expression is surprisingly low in tissues speciﬁcally involved in
FIGURE 3 | Light microscopy of dermal fibroblasts cultured for 3 weeks
in the presence of DMEM (A) or of DMEM supplemented with
ascorbate, beta-glycerophosphate, and dexamethasone (B). In the
presence of the calciﬁed medium, dermal ﬁbroblasts exhibit areas of
mineralization that can be clearly visualized upon Von Kossa staining as dark
deposits (lower panel; see also Boraldi et al., in press, for methodological
details).
the clinical manifestations of PXE. In this context, it has been
suggested that a still unknown circulating metabolite released
(or not released) by the liver in ABCC6 deﬁciency may directly
affect elastic ﬁber formation, stability, and calciﬁcation (Le Saux
et al., 2006).
Actually, in a setting of normal calcemia and phosphatemia,
several abnormalities have been documented in the circulation of
PXE patients, from PGs and enzymes involved in their synthe-
sis (Götting et al., 2005; Schön et al., 2006; Volpi and Maccari,
2006), to protein and lipid abnormalities indices of oxidative
stress (Garcia-Fernandez et al., 2008), to high levels of MMP2 and
MMP9 (Diekmann et al., 2009) and of elastin-derived peptides
(Annovazzi et al., 2004; Table 1).
Moreover, low levels of fetuin A and of vitamin K have been
measured in the circulation of PXE patients and in the PXE animal
model (Jiang et al., 2010;Vanakker et al., 2010). Low levels of fetuin
A could be explained by the augmented capture of this molecule
by peripheral mineral precipitates (Price et al., 2004; Hendig et al.,
2006), although it cannot be excluded that PXE ﬁbroblasts may
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Circulating ion levels Normal Ca and P (Boraldi et al., in press)
Phosphate
homeostasis
Normal serum alkaline phosphatase (ALP;
Boraldi et al., in press)
↑TNAP in ﬁbroblasts (Boraldi et al., in press)
Calciﬁcation inhibitors ↓ Gla-MGP (Gheduzzi et al., 2007; Li et al., 2007;
Hendig et al., 2008b)
↓ Fetuin-A (Hendig et al., 2006; Jiang et al.,
2010)
Polymorphisms of OPN (Hendig et al., 2007)
Mutation of ENPP1 (Nitschke et al., 2012)
Extracellular matrix
components
↑ MMP2, MMP9 in serum (Diekmann et al.,
2009)
↑ MMP2 in ﬁbroblasts (Quaglino et al., 2005)
Polymorphisms of MMP2 (Zarbock et al., 2010)
↑ Elastin-derived peptides (Annovazzi et al.,
2004)
Different ratio PG/GAGs (Tiozzo-Costa et al.,
1988; Passi et al., 1996; Maccari andVolpi, 2008)
↑ Circulating selectins (Götting et al., 2008)
↑ Serum intercellular adhesion molecule (ICAM;
Hendig et al., 2008a)
Different expression of integrins (Quaglino et al.,
2000)
↑ Serum XT-I activities (Götting et al., 2005)
Polymorphisms of XT-I (Schön et al., 2006)
Redox balance ↑ ROS in serum (Garcia-Fernandez et al., 2008)
↑ ROS in ﬁbroblasts (Pasquali-Ronchetti et al.,
2006; Boraldi et al., 2009)
Polymorphisms of antioxidant genes
(Zarbock et al., 2007)
sequester this inhibitor (Boraldi et al., 2007) as a consequence of
higher intracellular uptake that may prevent fetuin A from exert-
ing its regulatory role in peripheral tissues. The recent ﬁnding that
in the mouse model of PXE ectopic calciﬁcation can be signiﬁ-
cantly reduced by overexpressing fetuin A (Jiang et al., 2010) may
suggest that in PXE the role of this inhibitor should be further
investigated.
Nevertheless, it is unlikely that all these plasma abnormali-
ties in PXE patients would directly depend on the deﬁciency of
the membrane transporter MRP6. It would seems more reason-
able that inherited ABCC6 deﬁciency, along the years, would
induce a series of metabolic adjustments in several tissues pos-
sibly epigenetically involving a network of different genes and
leading to the complexity and heterogeneity of PXE alterations.
Moreover, since each patient has a different genetic background,
the consequences of these “metabolic adjustments” would be
different in each individual thus explaining the extreme variability
of clinical manifestations among patients.
Therefore, clinical and experimental data strongly suggest that
elastic ﬁber calciﬁcation in PXE is not a passive process merely
due to the presence or absence of one or more abnormal plasma
components, but the result of activities mediated by local cells.
At least in skin, ﬁbroblasts should be considered the principal
candidates for several reasons.
First of all, if elastic ﬁber calciﬁcations in PXE are a passive pro-
cess due to the inﬁltration of plasma molecule(s), all elastic ﬁbers
should calcify; on the contrary, skin elastic ﬁber calciﬁcation is
present only in peculiar regions of the body. Moreover, also in
areas prone to calciﬁcation, not all elastic ﬁbers mineralize. This is
in agreementwith the overgrowing evidence of the diversity of skin
ﬁbroblasts at different anatomical sites, as these cells display dis-
tinct and characteristic transcriptional patterns for a large number
of genes depending on the body region they come from (Chang
et al., 2002; Lindner et al., 2012). Therefore, skin ﬁbroblastsmay be
considered differentiated cell types that, depending on their loca-
tion, maintain their positional identities even when isolated and
cultured in vitro (Rinn et al., 2008) and probably react in different
ways to abnormal exogenous stimula, such as those present in the
circulation of PXE patients.
A second evidence for the involvement of ﬁbroblasts in skin
abnormalities in PXE is, beside elastic ﬁber calciﬁcation, the
documented presence of huge aggregates of PGs and of various
extracellular matrix proteins in the affected areas of the der-
mis (Pasquali-Ronchetti et al., 1986; Tiozzo-Costa et al., 1988;
Baccarani-Contri et al., 1994; Passi et al., 1996), consistent with
a signiﬁcant increase of the total amount of GAGs in the skin of
patients (Maccari and Volpi, 2008; Table 1) and with the observed
decreased susceptibility of GAG-associated elastin to pancreatic
elastase (Schwartz et al., 1991). Such structural and chemical alter-
ations, very likely responsible for skin redundancy and laxity in the
affected areas,must be under the local control of ﬁbroblasts, which
are responsible for the synthesis of the extracellular milieu in soft
connective tissues.
An indirect indication that also in the vessel wall ﬁbroblasts
are probably involved in the early calciﬁcation of elastic ﬁbers is
the observation that calciﬁcation in PXE vessels is often present
within the elastic ﬁbers close to the adventitia, in the absence of
any osteoblast-like phenotype of the adjacent cells, that in fact
maintain a ﬁbroblast-like appearance (Gheduzzi et al., 2003).
Finally, several studies by our and other groups have shown
that ﬁbroblasts isolated from the dermis of PXE patients have and
maintain in vitro a metabolic behavior different from ﬁbroblasts
isolated from the same body areas of gender and age-matched nor-
mal subjects. Actually, it has been demonstrated that PXE ﬁbrob-
lasts suffer from an oxidative stress condition (Pasquali-Ronchetti
et al., 2006), produce highly sulfated GAGs (Tiozzo-Costa et al.,
1988; Passi et al., 1996), exhibit abnormal proteoglycanase (Gor-
don et al., 1978, 1983) and higher metalloproteinase activities
(Quaglino et al., 2005), are unable to properly carboxylate MGP
(Gheduzzi et al., 2007; Boraldi et al., in press; Table 1), and have a
different protein proﬁle (Boraldi et al., 2009) indicating that their
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metabolic behavior is genetically or epigenetically different from
control ﬁbroblasts and is maintained when cells are cultured in
vitro (Rinn et al., 2008).
In the light of these observations, dermal ﬁbroblasts from PXE
patients can be considered a valuable and very informative model
to better understand the contribution of these cells to soft connec-
tive tissue calciﬁcations. Therefore, beside the role of ﬁbroblasts
in regulating the characteristics of the extracellular environment
and, as a consequence, the different susceptibility of tissues and of
elastic ﬁbers to calcify, a key question remains whether the same
osteoblast-related pathways, as those described in SMC, are also
involved in the phenotype of ﬁbroblasts prone to calcify (i.e., PXE
ﬁbroblasts).
Recent evidence fromour laboratory indicates that TNAPactiv-
ity, although within normal range in the circulation of patients,
is higher in PXE ﬁbroblasts compared to control cells and that
these differences are further ampliﬁed when cells are grown in
a calcifying medium. The process is rather complex, however,
data suggested that the local increase of phosphorus in the extra-
cellular milieu together with the reduced amount of anti-calciﬁc
molecules, such as carboxylated MGP, may favor hydroxyapatite
formation (Boraldi et al., in press).
Interestingly, low levels of MGP have been found in the circu-
lation of PXE patients (Hendig et al., 2008b) and in the Abcc6−/−
mice model of PXE (Li et al., 2007). In accordance, low levels
of carboxylated MGP are produced by skin PXE ﬁbroblasts in
vitro, indicating that the local synthesis of the mature protein is
of paramount importance in preventing elastic ﬁber calciﬁcation
(Gheduzzi et al., 2007) and that ﬁbroblasts are likely involved in the
local secretion of this important anti-calciﬁc protein. Since MGP
γ-carboxylation is a vitamin K-dependent process (Theuwissen
et al., 2012), it was suggested that PXE calciﬁcation could be due
to vitamin K deﬁciency (Borst et al., 2008). Although the level of
vitamin K is low in PXE patients (Vanakker et al., 2010), never-
theless the availability and the cellular utilization of vitamin K do
not seem responsible for MGP under-carboxylation. Both in PXE
ﬁbroblasts and in two different Abcc6−/− mice models, addition
of vitaminKdid not improveMGP carboxylation (Boraldi et al., in
press) nor prevented calciﬁcation in spite of the high serum con-
centration of vitamin K upon treatments (Brampton et al., 2011;
Gorgels et al., 2011; Jiang et al., 2011). Therefore, low vitamin K
does not seem to play a pivotal role in MGP carboxylation nor
in elastic ﬁber calciﬁcation in PXE. Moreover, in PXE, carboxy-
lation of proteins involved in coagulation or in bone calciﬁcation
seems adequate, as no defects in coagulation or in bone mineral-
ization have been described in patients. Therefore, both vitamin
K availability and the carboxylase system do not seem directly
involved in PXE mineralization. Recent data from our laboratory
seem to suggest that the low carboxylation rate of MGP by PXE
skin ﬁbroblasts, even in a setting of high vitamin K concentration,
might depend on the intrinsic ability of MGP to be carboxylated
(Boraldi et al., in press)
In addition, evidence has been provided through the years that
the PXE phenotype can be obtained through pathways other than
those caused byABCC6 mutations. An indirect proof of this is that
PXE-like clinical and histo-pathological manifestations have been
described in a number of patients affected by beta-thalassemia
(Aessopos et al., 1992, 1998; Baccarani-Contri et al., 2001; Cian-
ciulli et al., 2002) and other hemoglobinopathies (Goldberg et al.,
1971; Nagpal et al., 1976; Aessopos et al., 2002; Fabbri et al., 2009),
in subjects treated with penicillamine (Rath et al., 2005), in cases
of γ-carboxylase gene (GGCX) and ENPP1 mutations (Vanakker
et al., 2007; Le Boulanger et al., 2010; Li et al., 2012; Nitschke et al.,
2012; see further for additional data) and, more recently, in a few
cases of liver transplantation where the impossibility to examine
the DNA from all donors and recipients made not clear if the




As already mentioned, the metabolic complexity at the basis of
elastic ﬁber calciﬁcation could, at least partially, explain the phe-
notypic similarities of the skin lesions in inherited PXE and in a
number of different unrelated disorders, such as in patients
affected by beta-thalassemia (Aessopos et al., 1992; Baccarani-
Contri et al., 2001).
More than 60 years ago, elastinopathies similar to that in PXE
were documented in sickle cell anemia (Paton, 1959; Suerig and
Siefert, 1964) and, later, in a series of hemoglobinopathies (Nag-
pal et al., 1976), among which β-thalassemia (Aessopos et al., 1992,
1997). Subsequent studies better deﬁned the almost identical clin-
ical and histo-pathological alterations in PXE and in a relevant
number of β-thalassemia patients (Aessopos et al., 1998). In both
these unrelated genetic disorders, angioid streaks (Gibson et al.,
1983; Kinsella and Mooney, 1988; Aessopos et al., 1989, 1992;
O’Donnell et al., 1991), arterial elastorrhexis, and calciﬁcation
(Aessopos et al., 1998; Tsomi et al., 2001; Cianciulli et al., 2002)
as well as coalescent skin papules on the posterior/lateral aspect
of neck, axillae, and groin with elastic ﬁber calciﬁcation (Aesso-
pos et al., 1992; Baccarani-Contri et al., 2001) have been repeatedly
described.
Skin abnormalities in genetic PXE and in beta-thalassemia
patients with clinical PXE-like manifestations (β-thal/PXE) have
been carefully analyzed. It was observed that both disorders had
identical elastic ﬁber calciﬁcations, “collagen ﬂowers” abnormali-
ties, as well as cell and matrix alterations, suggesting that similar
metabolic changes could be involved in both disorders as ﬁnal
consequence of mutations in apparently unrelated genes.
In agreement with this hypothesis are data from experiments
aiming to verify if the similarities of clinical and histo-pathological
features in genetic PXE and in β-thal/PXE patients could be sus-
tained by analogous similarities in the metabolic behavior of
cultured ﬁbroblasts.
Fibroblasts from healthy subjects, from PXE patients as well
as from individuals affected by beta-thalassemia exhibiting (β-
thal/PXE) or not (β-thal) ectopic calciﬁcation, were investigated
for their ability to accumulate and to extrude calcein-AM (ace-
tomethoxy derivate of calcein; Boraldi et al., 2008), a chemical
widely used for determining cell viability. The non-ﬂuorescent
calcein-AM enters living cells where it is hydrolyzed by intracellu-
lar esterases into the strongly ﬂuorescent green anion calcein that
can be retained in the cytoplasm or actively extruded. The accu-
mulation and the extrusion of ﬂuorescent calcein can be easily
www.frontiersin.org March 2013 | Volume 4 | Article 22 | 9
“fgene-04-00022” — 2013/3/12 — 13:07 — page 10 — #10
Ronchetti et al. Fibroblasts in ectopic calciﬁcations
visualized by confocal microscopy and quantiﬁed by ﬂow cytom-
etry (Boraldi et al., 2003). Within few minutes of incubation with
calcein-AM (0.1 μM) dermal ﬁbroblasts accumulate the ﬂuores-
cent molecule into discrete granules in the cytoplasm. After a
30-minute incubation, calcein accumulation is much higher in
PXE and in β-thal/PXE cells than in controls and in β-thal ﬁbrob-
lasts. Furthermore, also calcein efﬂux from β-thal/PXE ﬁbroblasts
is signiﬁcantly different compared to controls (p < 0.05), whereas
it is identical to that of ﬁbroblasts frompatientswith inheritedPXE
(Figure 4). Therefore, in vitro dermal ﬁbroblasts from β-thal/PXE
patients, in the absence of ABCC6 mutations (Hamlin et al., 2003),
exhibit functional alterations similar to those of ﬁbroblasts isolated
from patients with inherited PXE. In this speciﬁc case, the calcein
assay is defective in ﬁbroblasts isolated from subjects with identical
elastic ﬁber calciﬁcation (i.e., PXE and β-thal/PXE), whereas it is
normal in ﬁbroblasts from β-thalassemia patients without PXE-
like clinical alterations. Therefore, these ﬁndings further support
the hypothesis that PXE-like clinical manifestations described in
some β-thalassemia patients might derive from metabolic alter-
ations occurring in this particular sub-group of patients and that
similar pathways may be at the basis of elastic ﬁber calciﬁcation in
inherited PXE and in β-thal/PXE patients (Boraldi et al., 2008).
In β-thalassemia patients an abnormal oxidative stress induced
by the iron overload derived from repeated transfusions, by
FIGURE 4 | Calcein uptake and extrusion in cultured fibroblasts
from healthy individuals (Control), PXE patients (PXE), beta-
Thalassemic patients with (βThal/PXE) and without (βThal) PXE-like
manifestations. Intracellular calcein accumulation is shown after 2 and
30 min by confocal microscopy (A). Calcein uptake (B) and extrusion
(C) have been measured by ﬂow cytometry and are shown in panels
on the right (see also Boraldi et al., 2003, for methodological
details).
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unpaired alpha-globin chains (Livrea et al., 1996; Hershko et al.,
1998; Cighetti et al., 2002) and by deﬁcient oxygen transport
to peripheral tissues (Chan et al., 1999; Meral et al., 2000) has
been described. How oxidative stress interferes with connec-
tive tissue metabolism is still largely unknown. It has been
shown that iron overload and the consequent oxidative stress
affect the synthesis of elastin by human dermal ﬁbroblasts in
vitro (Bunda et al., 2005) and that genetic factors as well as
environmental oxidative stress may deeply inﬂuence the extra-
cellular matrix and the behavior of cells in vivo (Hanley and
Repine, 1993). It could be suggested that clinical and histolog-
ical alterations in β-thal/PXE patients could be due, at least in
part, to chronic oxidative stress that, similarly to inherited PXE
(Garcia-Fernandez et al., 2008), is not adequately compensated
due to a peculiar genetic/epigenetic background. Interestingly,
the introduction of oral iron chelators markedly increased the
survival of β-thalassemia patients (Borgna-Pignatti et al., 2004)
and reduced the level of oxidative stress, in agreement with
the observation that PXE-like clinical manifestations are never
found in properly treated new β-thalassemia patients (personal
observation).
Interestingly, Hbbth3/+ mice are characterized by a signiﬁcant
liver-speciﬁc decrease of mrp6 production, due to failure of the
NF-E2p45 transcription factor to bind to the Abcc6 proximal
promoter. Even though this animal model of thalassemia is not
characterized by soft connective tissue mineralization, never the
less it demonstrates thatAbcc6 gene expression can be modiﬁed by
environmentally-induced changes in transcription factor activity
(Martin et al., 2011) and that oxidative stress could play a relevant
role. In this context, it is worthwhile to mention that there are
data in the literature in favor of a relationship between NF-E2p45
and Nrf2 transcription factors, as independent groups have shown
the role hemin in stimulating the expression of antioxidant heme
oxygenase 1 (Li et al., 2011) as well as in inducing beta-globin
gene expression through the functional intervention of p45NF-E2
transcription factor (Moore et al., 2006). Moreover, in favor of
a negative effect of oxidative stress on the expression of ABCC6
are data showing that vitamin K3 and oxidant agents induce
down-regulationofABCC6 expression inHepG2cells (DeBoussac
et al., 2010).
Deﬁcit of vitamin K-dependent gamma-carboxylase system
The vitamin K-dependent gamma-carboxylation system is com-
posed of the gamma-carboxylase and the warfarin-sensitive
enzyme vitamin K(1) 2,3-epoxide reductase (VKOR), which are
located in the endoplasmic reticulum where they interact with
other proteins like calumenin and protein disulﬁde isomerase,
negative and positive regulators of the vitamin K cycle, respec-
tively (Wajih et al., 2004; Wallin et al., 2008). Different expression
of these two regulatory proteins has been demonstrated on in vitro
cultured ﬁbroblasts to be probably involved in the pathogenesis of
PXE and of PXE-like calciﬁcations (Boraldi et al., 2009).
During vitamin K-dependent post-translational gamma-
glutamyl carboxylation, vitamin K hydroquinone is oxidized to
the epoxide form (K>O) that, in turn, is reduced by the enzyme
VKORC1 (vitamin K epoxide reductase complex component 1) to
complete the vitamin K cycle.
The demonstration that the enzyme VKORC1 is the target for
the anti-coagulant drug warfarin and that patients treated with
this drug develop extensive vascular calciﬁcations (Palaniswamy
et al., 2011) sustain the importance of the vitamin K-dependent
regulatory mechanisms of calciﬁcation. In particular, VKORC1
appears to be a rate-limiting step in the biosynthesis of functional
vitamin K-dependent proteins.
Interestingly, skin lesions due to elastic ﬁber calciﬁcation almost
identical to those in PXE have been described in cases of muta-
tions of GGCX (Vanakker et al., 2010). As already mentioned,
this enzyme is necessary for the γ-carboxylation of a number
of proteins some of which are involved in ectopic calciﬁcation
(Shanahan et al., 1998; Price et al., 2006). Therefore, mutations in
the GGCX gene are at the basis of an autosomal recessive dis-
order characterized by a generalized deﬁciency of the Vitamin
K-dependent clotting factors as well as mineralization and frag-
mentation of elastic ﬁbers leading to thickened, inelastic skin and
limited retinopathy, associated to accumulation of uncarboxylated
Gla proteins (MGP and OC) in plasma, serum and dermis, in
the presence of normal serum levels of vitamin K (McMillan and
Roberts, 1966). Even though, the deﬁcient carboxylation of coag-
ulation proteins can be restored by vitamin K administration that
increases the level of the electron-donor hydroquinone form of
vitaminK available forGGCX,never the less, 1 year treatmentwith
vitamin K did not ameliorate skin lesions nor elastic ﬁber calciﬁ-
cation in one patient affected by GGCX mutations (unpublished
observations). It could be suggested that carboxylase is essential
for maturation of MGP, but that the electron donor level of vita-
min K does not inﬂuence the performance of MGP carboxylation.
These data and those from other laboratories showing that vita-
min K supplementation does not increase the level of circulating
carboxylated MGP in a case of Keutel syndrome (MGP mutations;
Cranenburg et al., 2011) seem to indicate that MGP carboxylation
is under a complex control, only partly dependent on vitaminK, in
agreement with recent results obtained on PXE ﬁbroblasts treated
in vitro with vitamin K supplementation (Boraldi et al., in press).
To further enlarge the spectrum of ectopic calciﬁcation
disorders which are clinically and/or pathogenetically related to
PXE, there is a recent report describing a patient, bearing two
ABCC6 mutations and a gain of function single-nucleotide poly-
morphism (SNP) in the GGCX gene, who was characterized by
both classic PXE (papules, retinopathy, and calciﬁcations) and by a
PXE-like syndrome (cutis laxa beyond the ﬂexural areas; Vanakker
et al., 2011).
Mutations in the GGCX or VKORC1 genes are associated with
a hereditary deﬁciency of the vitamin K-dependent clotting fac-
tors as well as a clinically relevant dependency of anti-coagulants
(Brenner, 2000; Vanakker et al., 2010). Besides these enzymatic
defects, a deﬁciency of vitamin K has been described in associ-
ation with coagulation, bone (osteoporosis, osteoarthritis) and
vascular (arteriosclerosis) disorders resulting from insufﬁcient
carboxylation of Gla proteins (Neogi et al., 2006).
Generalized arterial calciﬁcation of infancy
Generalized arterial calciﬁcation of infancy is associated with
mutations in the ENPP1 gene and is characterized by mineral-
ization of the internal elastic lamina of large and medium-sized
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arteries and stenosis due to myointimal proliferation. Although
survival to adulthood has been reported, most patients die within
the ﬁrst 6 months of life (Rutsch et al., 2003).
Features of PXE have been recently described in patients
with homozygous missense mutation of the ENPP1 gene (Li
et al., 2012). Cutaneous calciﬁcation was never been previously
described in ENPP1 deﬁciency and this ﬁnding is a clear demon-
stration of the role of PPi as a critical anti-calciﬁc agent in PXE
and PXE-like disorders.
It is therefore noteworthy the occurrence of a clinical and
genetic overlapping between PXE and GACI as clearly high-
lighted by a recent study on two brothers born from to
unrelated parents, showing that the elder developed a PXE con-
dition bearing ABCC6 mutations, whereas the younger died
at 15 months of age of a condition clinically reminiscent of
GACI, although it appeared independent of ENPP1 mutations (Le
Boulanger et al., 2010).
The ﬁnding that MGP and fetuin A are involved in both
conditions further sustain the hypothesis that ABCC6 muta-
tions account for a signiﬁcant subset of GACI patients, and
ENPP1 mutations can also be associated with PXE lesions in
young children, thus reﬂecting two ends of a clinical spectrum
of ectopic calciﬁcations, possibly through the involvement of
common physiological pathways (Nitschke et al., 2012).
CONCLUSION
In spite of the extreme complexity and still incomplete knowledge
of the various actors involved, we have reported evidence sup-
porting the importance of mesenchymal cells, and of ﬁbroblasts
in particular, in the occurrence and development of soft connec-
tive tissue calciﬁcations. Within this context, ﬁbroblasts from PXE
andPXE-like disorders offer a valuablemodel to better understand
the complex pathways that end up with elastic ﬁber mineraliza-
tion. It can be argued that not all mesenchymal cells behave in the
same way and that morpho-functional characteristics of tissues
as well as composition of the extracellular matrix and exogenous
agents should be taken into account for understanding the sus-
ceptibility/resistance to calciﬁcation of different body regions in
physiological conditions, in aging and in both genetic and acquired
disorders.
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